Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price […]
More Stories
Weather System Off North Carolina Could Become Nor’Easter or Tropical Storm: What to Know
By T.J. Muscaro The National Weather Service and its National Hurricane Center are tracking a storm system sitting off the...
Wall Street Review: Nasdaq Sinks 4.48 Percent as Inflation Fears Hit AI Stocks
By Panos Mourdoukoutas The Nasdaq Composite fell 4.48 percent for the week as hotter-than-expected inflation data sent Treasury yields higher...
Republican Attorney General Candidate New York, Saritha Komatireddy, Lays Out Her Vision
By Juliette Fairley Fresh off a fiery political debate last week, Republican challenger Saritha Komatireddy on Oct. 15 laid out...
Chaos and Violence Grip France as Far-Left Mobs Storm City Halls, Torch Streets
By Etienne Fauchaire PARIS—Stones and fireworks were already flying across Place de la République before Saturday’s demonstration against rising costs...
High Gas Prices Could Be the Key Issue That Swings the Senate
By Jeremy Lott Enough voters are fixated on the price of fuel that it could be the deciding issue in...
Treasury Sanctions Iraqi Bank and Iranian Shadow Networks
By Kimberly Hayek The Treasury Department has sanctioned the Iraq-based International Development Bank for Investment and Finance (IDB) and related...